Thioridazine and EKG anomalies

Area of Science:

• Pharmacology
• Cardiology
• Veterinary Medicine

Background:

• Thioridazine hydrochloride is an antipsychotic medication.
• EKG anomalies have been reported in psychiatric patients taking thioridazine.
• The specific administration route and metabolites' effects on cardiac function require clarification.

Purpose of the Study:

• To investigate the cardiac effects of acute intravenous versus daily oral thioridazine hydrochloride in dogs.
• To compare the EKG effects of thioridazine and its metabolite, thioridazine-5-sulfoxide.
• To explore the relationship between drug plasma levels, metabolites, and observed EKG changes.

Main Methods:

• Administration of thioridazine hydrochloride via acute i.v. infusion and daily oral dosing in dogs.
• Administration of thioridazine-5-sulfoxide via i.v. infusion.
• Electrocardiogram (EKG) monitoring to assess cardiac anomalies.
• Dose-equivalent comparisons between thioridazine and its metabolite.

Main Results:

• Acute i.v. infusion of thioridazine-HCl induced EKG anomalies in dogs.
• Daily oral administration of thioridazine-HCl did not produce similar EKG anomalies.
• Infusion of thioridazine-5-sulfoxide at equivalent doses did not result in EKG anomalies.

Conclusions:

• The route of administration (acute i.v. vs. daily oral) significantly influences the cardiac effects of thioridazine hydrochloride.
• Thioridazine-5-sulfoxide does not appear to be responsible for the observed EKG anomalies.
• Further research is needed to elucidate the correlation between thioridazine plasma concentrations, its sulfoxide metabolite, and EKG alterations.